Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-216-2 | CAS number: 93-08-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Key value for chemical safety assessment
- Toxic effect type:
- dose-dependent
Effects on fertility
Description of key information
The Reproductive Toxicity Data:
In the present study, one generation reproductive toxicity test of test chemical was carried out and the toxicity of reproductive to male and female animals of test chemical was examined. In the study, animals were orally administered from 10 weeks of age including mated up to 3 weeks. The males were necropsied after one week passed after the mating period. Females were allowed to spontaneously deliver after mating and necropsied with their babies on nursing 21th. Both males and females continued to be administered until the day before necropsy, during which the general condition of the parent animal, weight gain and changes in food intake were observed, and at the same time the reproductive ability, including delivery and lactation of the parent animal, and weaning of the infant was observed. The results of the parenteral examination revealed that, no mortality in treated animals at 10, 40 and 160mg/kg/day for 10 weeks,including mating period, the clinical signs examination of animlas shows, nasal discharge, eyelid ptosis or closed eyes, in group administered with 40 mg / kg or more but not in 160mg/kg group , lacrimation in 160 mg / kg administration group was transiently observed. Salivation was observed in each administration group of the test substance.No test chemical related chnages on food consumption and body weight changes were observed. Spontaneous locomotor reduction and salivation were observed transiently after administration and no abnormality was observed in both treated males and femlaes. There was a decrease in locomotor activity, eyelid ptosis or closed eyes, and nasal discharge in group administered with 40 mg / kg or more, lacrimation in 160 mg / kg administration group. There was no change depending on the dose of the test substance in reproductive organsof male and females. The histopathological study relealed no abnormality in pituitary gland. In males, in each case in the 40 mg / kg and 160 mg / kg administration groups, the spermatogonia of the spermatogenic cells in the 14 th stage of the spermatogenesis cycle mild degeneration was observed, and cell debris was observed in the lumen of the epididymis in the example of 40 mg / kg administration group. Unilateral seminal vesicle atrophy was observed in each group including the control group. No abnormality were seen on seminal vesicle and Coagulated glands In females, no abnormality was observed in the pituitary gland, stomach, ovary, uterus, cervix and vagina. The fetal examination results revealed, deaths in 4 offspings of control group and 2 offsping of 10 mg / kg administration group, respectively. In addition, 3 out of 6 cases in the 40 mg / kg administration group and 22 cases out of 27 cases in the 160 mg / kg administration group were judged as stillbirth, but no clinical signs of toxicity on survived pups. There was no significant difference in body weight in male and female between the control group and each test group administered group at any time. No gross pathological changes were observed, At necropsy of born pups, morphological changes including malformations and mutations were observed in born pups 1-2 in each group including the control group. From the observation and results, the NOAEL for P0 generation and F1 generation was considered to be 160mg/kg/day and 40mg/kg/day respectively.
Link to relevant study records
- Endpoint:
- one-generation reproductive toxicity
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Justification for type of information:
- Data is from Ministry of Health, Labor and Welfare (MHW) report
- Qualifier:
- equivalent or similar to
- Guideline:
- OECD Guideline 415 [One-Generation Reproduction Toxicity Study (before 9 October 2017)]
- Principles of method if other than guideline:
- One generation reproductive toxicity test of test chemical was carried out and the toxicity of reproductive to male and female animals of test chemical was examined
- GLP compliance:
- yes
- Limit test:
- no
- Justification for study design:
- No data available
- Species:
- rat
- Strain:
- other: Sprague-Dawley strain (Crj: CD) rats
- Details on species / strain selection:
- No data available
- Sex:
- male/female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Tsukuba breeding center, Charles River Japan Co., Ltd.
- Age at study initiation: No data available
- Weight at study initiation: No data available
- Fasting period before study: No data available
- Housing: housed in a metallic wire mesh floor cage in a breeding room
- Use of restrainers for preventing ingestion (if dermal): yes/no: No data available
- Diet (e.g. ad libitum): No data available
- Water (e.g. ad libitum): tap water, provided ad libitum
- Acclimation period: No data available
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 24 ± 1 ° C
- Humidity (%): 50 to 65%
- Air changes (per hr): about 15 times / hour
- Photoperiod (hrs dark / hrs light): lighting for 12 hours - Route of administration:
- oral: gavage
- Type of inhalation exposure (if applicable):
- not specified
- Remarks on MMAD:
- No data available
- Vehicle:
- CMC (carboxymethyl cellulose)
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: The dosing solution was prepared by mixing the test chemical in vehicle with a magnetic stirrer
DIET PREPARATION
- Rate of preparation of diet (frequency): No data available
- Mixing appropriate amounts with (Type of food): No data available
- Storage temperature of food: No data available
VEHICLE
- Justification for use and choice of vehicle (if other than water):No data available
- Concentration in vehicle: No data available
- Amount of vehicle (if gavage): 5ml/kg
- Lot/batch no. (if required): No data available
- Purity:No data available - Details on mating procedure:
- Matings were conducted in males and females 1: 1 within the same group for a period of 3 weeks, and confirming the presence of sperm in the vaginal smear and confirming the vaginal plug every morning.
- Analytical verification of doses or concentrations:
- not specified
- Details on analytical verification of doses or concentrations:
- No data available
- Duration of treatment / exposure:
- 10 weeks (71 days of administration)
- Frequency of treatment:
- Daily
- Details on study schedule:
- No data available
- Remarks:
- 0 (vehicle control)= 25male and 25female
10mg/kg=25male and 25female
40mg/kg=25male and 25female
160 mg/kg=25male and 25female - No. of animals per sex per dose:
- 0 (vehicle control)= 25male and 25female
10mg/kg=25male and 25female
40mg/kg=25male and 25female
160 mg/kg=25male and 25female - Control animals:
- yes, concurrent vehicle
- Details on study design:
- Animals were orally administered from 10 weeks of age including mated up to 3 weeks. The males were necropsied after one week passed after the mating period. Females were allowed to spontaneously deliver after mating and necropsied with their babies on nursing 21th. Both males and females continued to be administered until the day before necropsy, during which the general condition of the parent animal, weight gain and changes in food intake were observed, and at the same time the reproductive ability, including delivery and lactation of the parent animal, and weaning of the infant was observed.
- Positive control:
- No data available
- Parental animals: Observations and examinations:
- Parent animals were observed for mortality, general condition, change in weight, food intake, estrus cycle assessment.
- Oestrous cyclicity (parental animals):
- Estrus cycle were determined before 2 weeks of start of mating confirmation day, two weeks before the start of administration and two weeks after the start of the administration.
- Sperm parameters (parental animals):
- Spermatogenesis cycle was observed in males
- Litter observations:
- Number of births, litter count and Weight measurement
- Postmortem examinations (parental animals):
- Animals were sacrificed to determined presence or absence of abnormalities of major organs thoracic abdomen, including the pituitary glands, stomach, testis, epididymis, coagulated glands, seminal vesicles, and prostate in males and pituitary, stomach, ovary, uterus, cervix and vagina in females
- Postmortem examinations (offspring):
- Offspings were sacrificed to determined presence or absence of abnormality on the external surface
- Statistics:
- Fisher's direct probability test 1) was carried out on frequency of type of sex cycle, mating rate, conception rate, morphological abnormality frequency of babiesAccording to histopathological examination findings, the Mann-Whitney U test 2)) shows the grade-separated data, and the total value of the positive grade is obtained by Fisher's direct probability one-sided test 3) between the control group and each test substance administration group Significant difference test was carried out. For the other data, we tested the uniformity of variance of each group by Bartlett method 4) , with the value obtained for each individual, or the average value for each litter as one sample . If the variance is uniform, a one-way analysis of variance 4) was performed, and when significance was observed between the groups, multiple comparisons were performed according to the Dunnett method 5) . On the other hand, Kruskal-Wallis 6) rank test is performed when the variance is 0 in any group and when the variance is not uniform, and if significance is observed between the groups.
- Reproductive indices:
- Conception rate was determined
- Offspring viability indices:
- No data available
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- Nasal discharge, eyelid ptosis or closed eyes, in group administered with 40 mg / kg or more but not in 160mg/kg group , lacrimation in 160 mg / kg administration group was transiently observed Salivation was observed in each administration group of the test substance.
- Dermal irritation (if dermal study):
- not specified
- Mortality:
- no mortality observed
- Description (incidence):
- In males, one patient in the 160 mg / kg dose group died on the 60th day of administration.
In females, there were no deaths or moribund - Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- No significant difference between the control group and each test group administered group
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- In males no change in food consumption were observed, however in females no change in food consumption uring the period before mating, but significantly lower values than control group, after pregnancy and during the nursing stage
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- not specified
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- no effects observed
- Description (incidence and severity):
- Spontaneous locomotor reduction and salivation were observed transiently after administration and no abnormality was observed in both treated males and femlaes. There was a decrease in locomotor activity, eyelid ptosis or closed eyes, and nasal discharge in group administered with 40 mg / kg or more, lacrimation in 160 mg / kg administration group.
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- not specified
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No abnormality was observed in pituitary gland. In males, in each case in the 40 mg / kg and 160 mg / kg administration groups, the spermatogonia of the spermatogenic cells in the 14 th stage of the spermatogenesis cycle mild degeneration was observed, and cell debris was observed in the lumen of the epididymis in the example of 40 mg / kg administration group. Unilateral seminal vesicle atrophy was observed in each group including the control group. no avnormality were seenon seminal vesicle and Coagulated glands In females, no abnormality was observed in the pituitary gland, stomach, ovary, uterus, cervix and vagina.
- Histopathological findings: neoplastic:
- not specified
- Other effects:
- effects observed, treatment-related
- Description (incidence and severity):
- Hair loss was observed in all the treated animals
- Reproductive function: oestrous cycle:
- no effects observed
- Description (incidence and severity):
- No significant difference were observed in estrus cycle after administration in each group including the control group
- Reproductive function: sperm measures:
- no effects observed
- Reproductive performance:
- no effects observed
- Description (incidence and severity):
- No significant difference between the conception rate, number of estrus periods in control and treated groups at 10, 40 and 160mg/kg. There was no significant difference in number of implantation between the control group and each test chemical treated groups.
- Dose descriptor:
- NOAEL
- Effect level:
- 160 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- clinical signs
- mortality
- body weight and weight gain
- food consumption and compound intake
- gross pathology
- histopathology: non-neoplastic
- reproductive function (oestrous cycle)
- reproductive function (sperm measures)
- reproductive performance
- Critical effects observed:
- not specified
- Clinical signs:
- no effects observed
- Dermal irritation (if dermal study):
- not specified
- Mortality / viability:
- mortality observed, treatment-related
- Description (incidence and severity):
- Deaths observed in 4 offspings of control group and 2 offsping of 10 mg / kg administration group, respectively. In addition, 3 out of 6 cases in the 40 mg / kg administration group and 22 cases out of 27 cases in the 160 mg / kg administration group were judged as stillbirth
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- There was no significant difference between male and female between the control group and each test group administered group at any time.
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- not specified
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Sexual maturation:
- not specified
- Organ weight findings including organ / body weight ratios:
- not specified
- Gross pathological findings:
- no effects observed
- Histopathological findings:
- no effects observed
- Description (incidence and severity):
- At necropsy of born pups, morphological changes including malformations and mutations were observed in born pups 1-2 in each group including the control group.
- Other effects:
- not specified
- Behaviour (functional findings):
- not specified
- Developmental immunotoxicity:
- not specified
- Key result
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- 40 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- clinical signs
- body weight and weight gain
- histopathology: non-neoplastic
- Critical effects observed:
- not specified
- Key result
- Reproductive effects observed:
- not specified
- Treatment related:
- not specified
- Conclusions:
- From the observation and results, the NOAEL for P0 generation and F1 generation was considered to be 160mg/kg/day and 40mg/kg/day respectively.
- Executive summary:
In the present study, one generation reproductive toxicity test of test chemical was carried out and the toxicity of reproductive to male and female animals of test chemical was examined. In the study, animals were orally administered from 10 weeks of age including mated up to 3 weeks. The males were necropsied after one week passed after the mating period. Females were allowed to spontaneously deliver after mating and necropsied with their babies on nursing 21th. Both males and females continued to be administered until the day before necropsy, during which the general condition of the parent animal, weight gain and changes in food intake were observed, and at the same time the reproductive ability, including delivery and lactation of the parent animal, and weaning of the infant was observed. The results of the parenteral examination revealed that, no mortality in treated animals at 10, 40 and 160mg/kg/day for 10 weeks,including mating period, the clinical signs examination of animlas shows, nasal discharge, eyelid ptosis or closed eyes, in group administered with 40 mg / kg or more but not in 160mg/kg group , lacrimation in 160 mg / kg administration group was transiently observed. Salivation was observed in each administration group of the test substance.No test chemical related chnages on food consumption and body weight changes were observed. Spontaneous locomotor reduction and salivation were observed transiently after administration and no abnormality was observed in both treated males and femlaes. There was a decrease in locomotor activity, eyelid ptosis or closed eyes, and nasal discharge in group administered with 40 mg / kg or more, lacrimation in 160 mg / kg administration group. There was no change depending on the dose of the test substance in reproductive organsof male and females. The histopathological study relealed no abnormality in pituitary gland. In males, in each case in the 40 mg / kg and 160 mg / kg administration groups, the spermatogonia of the spermatogenic cells in the 14 th stage of the spermatogenesis cycle mild degeneration was observed, and cell debris was observed in the lumen of the epididymis in the example of 40 mg / kg administration group. Unilateral seminal vesicle atrophy was observed in each group including the control group. No abnormality were seen on seminal vesicle and Coagulated glands In females, no abnormality was observed in the pituitary gland, stomach, ovary, uterus, cervix and vagina. The fetal examination results revealed, deaths in 4 offspings of control group and 2 offsping of 10 mg / kg administration group, respectively. In addition, 3 out of 6 cases in the 40 mg / kg administration group and 22 cases out of 27 cases in the 160 mg / kg administration group were judged as stillbirth, but no clinical signs of toxicity on survived pups. There was no significant difference in body weight in male and female between the control group and each test group administered group at any time. No gross pathological changes were observed, At necropsy of born pups, morphological changes including malformations and mutations were observed in born pups 1-2 in each group including the control group. From the observation and results, the NOAEL for P0 generation and F1 generation was considered to be 160mg/kg/day and 40mg/kg/day respectively.
Reference
Effect on fertility: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 160 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- The data is K2 level and provides robbust summary
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Additional information
The Reproductive Toxicity Data:
Study 2:
In the present study, one generation reproductive toxicity test of test chemical was carried out and the toxicity of reproductive to male and female animals of test chemical was examined. In the study, animals were orally administered from 10 weeks of age including mated up to 3 weeks. The males were necropsied after one week passed after the mating period. Females were allowed to spontaneously deliver after mating and necropsied with their babies on nursing 21th. Both males and females continued to be administered until the day before necropsy, during which the general condition of the parent animal, weight gain and changes in food intake were observed, and at the same time the reproductive ability, including delivery and lactation of the parent animal, and weaning of the infant was observed. The results of the parenteral examination revealed that, no mortality in treated animals at 10, 40 and 160mg/kg/day for 10 weeks,including mating period, the clinical signs examination of animlas shows, nasal discharge, eyelid ptosis or closed eyes, in group administered with 40 mg / kg or more but not in 160mg/kg group , lacrimation in 160 mg / kg administration group was transiently observed. Salivation was observed in each administration group of the test substance.No test chemical related chnages on food consumption and body weight changes were observed. Spontaneous locomotor reduction and salivation were observed transiently after administration and no abnormality was observed in both treated males and femlaes. There was a decrease in locomotor activity, eyelid ptosis or closed eyes, and nasal discharge in group administered with 40 mg / kg or more, lacrimation in 160 mg / kg administration group. There was no change depending on the dose of the test substance in reproductive organsof male and females. The histopathological study relealed no abnormality in pituitary gland. In males, in each case in the 40 mg / kg and 160 mg / kg administration groups, the spermatogonia of the spermatogenic cells in the 14 th stage of the spermatogenesis cycle mild degeneration was observed, and cell debris was observed in the lumen of the epididymis in the example of 40 mg / kg administration group. Unilateral seminal vesicle atrophy was observed in each group including the control group. No abnormality were seen on seminal vesicle and Coagulated glands In females, no abnormality was observed in the pituitary gland, stomach, ovary, uterus, cervix and vagina. The fetal examination results revealed, deaths in 4 offspings of control group and 2 offsping of 10 mg / kg administration group, respectively. In addition, 3 out of 6 cases in the 40 mg / kg administration group and 22 cases out of 27 cases in the 160 mg / kg administration group were judged as stillbirth, but no clinical signs of toxicity on survived pups. There was no significant difference in body weight in male and female between the control group and each test group administered group at any time. No gross pathological changes were observed, At necropsy of born pups, morphological changes including malformations and mutations were observed in born pups 1-2 in each group including the control group. From the observation and results, the NOAEL for P0 generation and F1 generation was considered to be 160mg/kg/day and 40mg/kg/day respectively.
Study 3:
One-Generation Reproduction Toxicity Test of test chemical in Rats was performed to estimate the reproductive toxicity profile. In the present study dose levels of 0, 12.5 ,50 and 200mg/kg used for the 10 weeks of exposure (71 dose administration) including mating period of 3 weeks. The treated animals observed for general condition, body weight measurement and food intake. Red blood cell count and white blood cell count was also measured. Estrus cycle during exposure was estimated. The offsprings were examined for number of births, general condition, number of deceased offspings, litter count, body weight, sex ratio and survival rate were measured.The postmortem of parenteral animals was carried out to examine major thoracic abdominal organs including the pituitary gland, stomach, adrenal glands, testis, epididymis, coagulated glands, seminal vesicles, prostate,ovaries, uterus and vagina. All surviving infants were necropsied by sacrificing all cases by ether inhalation on the 21th birth. At that time, the organ in which abnormality was observed. The dead child was autopsy examined for the presence or absence of abnormality on the external surface. The results of the parenteral observations revealed, transient salivation after test chemical administration in the 200 mg / kg group in both males and female. One case in the control group died due to poor feeding due to irregular occlusion. In addition, each one of 12.5 and 50 mg / kg administration group was moribund slaughtered or died by myeloid leukemia, but neither was caused by administration of the test substance. No death or moribund was observed in other treated animals. In test chemical treated males, suppression of body weight gain was observed at the end of treatment and in females, suppression of body weight gain was observed between the early stage of administration of 200 mg / kg administration group and the middle stage of pregnancy to postpartum nursing, but the effects of administration was not observed in food intake. No change in food consumption were seen at any dose levels at 12.5, 50 and 200mg/kg/day compared to control animals. The increase in the number of red blood cells(RBC) in the administration group of 50 mg / kg or more, no change related to the administration of the test substance was observed. At necropsy, hyperplasia of the forestomach mucosa was observed in the 200 mg / kg dose group.. In the 200 mg / kg administration group, attenuation of the degree of periportal fatty liver in the liver was also observed. For the liver, swelling was also observed at autopsy, but no distinct tissue change associated with swelling was observed. Histopathological examination of tissues revealed, no change due to administration of the test substance. In addition, changes in the pituitary, testis, epididymis, coagulated glands, seminal vesicles and prostate did not occur in any of the administration groups. In females, hyperplasia of squamous epithelium of forestomachial mucosa, but adrenal gland, pituitary gland, ovary , Uterus, uterine cervix and vagina, no change due to administration of the test substance was observed. The observations of neonates revealed, no mortality at all dose levels at 12.5,50 and 200mg/kg/day. No clinical signs of toxicity were seen at all dose levels at 12.5, 50 and 200mg/kg/day. The body weight of the 200 mg / kg administration group decreased from birth date to 21 days after birth, and growth inhibition ranging from fetal stage to nursing stage was observed. The frequency of things with external malformations such as the tail, short tail, short bending tail or small eye slightly increased in the 200 mg / kg administration group. In the 200 mg / kg administration group, abnormalities in the testis and hypoplasia of the spleen and visceral malformation of the diaphragmatic hernia were also observed. From the observations and results, the NOAEL for parents and neonates was considered to be 200mg/kg/day and 50mg/kg/day respectively.
Study 4:
One generation reproductive toxicity study of test material was performed according to OECD Guideline 415. The test material mixed with diet in dose concentration 0, 100, 500 and 2500 ppm and adminstered to groups of 25 rats per sex per group. Males were treated for 10 weeks and during the mated period and females for at least two weeks before mating until sacrifice. Body weights were recorded weekly during gestation period and at days 1, 4, 7, 14 and 21 during lactation period. Food consumption was measured weekly during experimental period. Food intake was recorded on presumed gestation days 7, 14 and 20 and on lactation days 4, 7, 14, 18 and 21. At birth, the number of pups born, sex and body weight of individual pups on days 1 and 4 were recorded. After standardization of litter size to 8 pups, pups were weighed individually on days 7, 14 and 21 of lactation. On day of weaning sacrifice (day 21), only one randomly selected pup per sex per litter was submitted to macroscopic examination. Fertility index for dams, sires and pup survival index were calculated. On completion of the gross pathology examination, the following tissues and organs were preserved in 10% neutral buffered formalin and submitted to microscopic examination: grossly abnormal tissues, ovaries, uterus, vagina, testes, epididymides, seminal vesicles, prostate, coagulating glands, pituitary gland and target organs of all P animals. The number of corpora lutea and implantation sites were recorded for all the dams. Histopathological examination of the parents was initially restricted to preserved organs from control and high dose group animals.
There were significant lower body weights from control at high dose in males from weeks 2 to 6 and at week 8 associated with a significant lower food intake at weeks 2 and 8 at high dose in males. There was also a significant decrease in bodyweights at day 20 of the gestation period in females of the high dose group, also observed at days 4, 7 and 14 of lactation period. A statistically significant increase in relative kidney weights at mid dose in males and at high dose for males and females was observed. The increased kidney weights observed in males and females were minimal in nature (<12%) and were not associated with microscopic changes, hence considered as toxicologically insignificant changes. A statistically significant increase in relative epididymides was also recorded at high dose in males but with no related microscopic changes in left epididymides. Further, there were no corresponding change in the weight of right cauda epididymides and epididymal sperm count therefore the increased epididymal weights were considered as incidental changes.There were no test item related changes in sperm motility, cauda epididymal sperm counts and sperm morphology parameters. However, a statistically significant increase in percentage of abnormal sperms was observed in high dose males but this observed change was within the historical control data. Moreover, no fertility parameters were affected and there were no changes in the testes or epididymis grossly or histopathologically therefore, considered incidental and not related to the treatment. There were no test item related gross findings in males and females. Only single incidences of several gross findings observed in different groups were considered as incidental without any relation to test item administration. There were no test item related microscopic changes in males and females. All single or few incidences of microscopic findings observed in males and females were considered as incidental findings. The mean number and weight of male, female and total pups per litter at all the doses tested were unaffected by treatment. No treatment-related changes were observed in the data of pups up to lactation day 21 at all the doses tested. HenceNo Observed Adverse Effect Level (NOAEL) for maternal and developmental toxicity was considered to be2500 ppm which is equivalent to 153.8 mg/kg Bwt/day for males and 393.6 mg/kg Bwt/day for females,.When male and femalerats were treated withtest chemical orallyover one generation.
Effects on developmental toxicity
Description of key information
The Developmental Toxicity Data :
In the present study, developmental toxicity test of test chemical was carried out and the developmental toxicity profile to male and female animals of test chemical was examined. In the study, animals were orally administered from 10 weeks of age including mated up to 3 weeks. The males were necropsied after one week passed after the mating period. Females were allowed to spontaneously deliver after mating and necropsied with their babies on nursing 21th. Both males and females continued to be administered until the day before necropsy, during which the general condition of the parent animal, weight gain and changes in food intake were observed, and at the same time the reproductive ability, including delivery and lactation of the parent animal, and weaning of the infant was observed. The results of the parenteral examination revealed that, no mortality in treated animals at 10, 40 and 160mg/kg/day for 10 weeks,including mating period, the clinical signs examination of animlas shows, nasal discharge, eyelid ptosis or closed eyes, in group administered with 40 mg / kg or more but not in 160mg/kg group , lacrimation in 160 mg / kg administration group was transiently observed. Salivation was observed in each administration group of the test substance.No test chemical related chnages on food consumption and body weight changes were observed. Spontaneous locomotor reduction and salivation were observed transiently after administration and no abnormality was observed in both treated males and femlaes. There was a decrease in locomotor activity, eyelid ptosis or closed eyes, and nasal discharge in group administered with 40 mg / kg or more, lacrimation in 160 mg / kg administration group. There was no change depending on the dose of the test substance in reproductive organsof male and females. The histopathological study relealed no abnormality in pituitary gland. In males, in each case in the 40 mg / kg and 160 mg / kg administration groups, the spermatogonia of the spermatogenic cells in the 14 th stage of the spermatogenesis cycle mild degeneration was observed, and cell debris was observed in the lumen of the epididymis in the example of 40 mg / kg administration group. Unilateral seminal vesicle atrophy was observed in each group including the control group. No abnormality were seen on seminal vesicle and Coagulated glands In females, no abnormality was observed in the pituitary gland, stomach, ovary, uterus, cervix and vagina. The maternal developmental toxicity includes, Implantation number in treated animals was equivalent to control animals. The litter size was significantly low value in 160mg/kg/day group compared to control group. No change in pregnancy duration were seen in treated females. No abnormality in labor condition was observed, and there was no effect on birth rate. The examination of pups revealed, body weight at the postnatal day 21 was slightly lower in the 160 mg / kg administration group. Number of live pups examined reduced in highest dosed group. There was no effect of administration on sex ratio. The litter size after adjustment of litter size was decreased in 160mg/kg/day group. In 160mg/kg /day group the postnatal survival declines comapared to control.No morphological changes including external, skeletal and visceral malformations where seen in treated animals. From the observation and results, the NOAEL for P0 generation and F1 generation was considered to be 160mg/kg/day and 40mg/kg/day respectively.
Link to relevant study records
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Justification for type of information:
- Data is from Ministry of Health, Labor and Welfare report
- Qualifier:
- according to
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Deviations:
- yes
- Principles of method if other than guideline:
- Developmental toxicity test of test chemical was carried out in Sprague-Dawley rats.
- GLP compliance:
- not specified
- Limit test:
- no
- Species:
- rat
- Strain:
- other: Sprague-Dawley strain (Crj: CD) rats
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Tsukuba breeding center, Charles River Japan Co., Ltd.
- Age at study initiation: No data available
- Weight at study initiation: No data available
- Fasting period before study: No data available
- Housing: housed in a metallic wire mesh floor cage in a breeding room
- Use of restrainers for preventing ingestion (if dermal): yes/no: No data available
- Diet (e.g. ad libitum): No data available
- Water (e.g. ad libitum): tap water, provided ad libitum
- Acclimation period: No data available
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 24 ± 1 ° C
- Humidity (%): 50 to 65%
- Air changes (per hr): about 15 times / hour
- Photoperiod (hrs dark / hrs light): lighting for 12 hours - Route of administration:
- oral: gavage
- Type of inhalation exposure (if applicable):
- not specified
- Vehicle:
- CMC (carboxymethyl cellulose)
- Remarks on MMAD:
- No data available
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: The dosing solution was prepared by mixing the test chemical in vehicle with a magnetic stirrer
DIET PREPARATION
- Rate of preparation of diet (frequency): No data available
- Mixing appropriate amounts with (Type of food): No data available
- Storage temperature of food: No data available
VEHICLE
- Justification for use and choice of vehicle (if other than water):No data available
- Concentration in vehicle: No data available
- Amount of vehicle (if gavage): 5ml/kg
- Lot/batch no. (if required): No data available
- Purity:No data available - Analytical verification of doses or concentrations:
- not specified
- Details on analytical verification of doses or concentrations:
- No data available
- Details on mating procedure:
- Matings were conducted in males and females 1: 1 within the same group for a period of 3 weeks, and confirming the presence of sperm in the vaginal smear and confirming the vaginal plug every morning.
- Duration of treatment / exposure:
- 10 weeks (71 days of administration)
- Frequency of treatment:
- Daily
- Duration of test:
- No data available
- Remarks:
- 0 (vehicle control)= 25male and 25female
10mg/kg=25male and 25female
40mg/kg=25male and 25female
160 mg/kg=25male and 25female - No. of animals per sex per dose:
- 0 (vehicle control)= 25male and 25female
10mg/kg=25male and 25female
40mg/kg=25male and 25female
160 mg/kg=25male and 25female - Control animals:
- yes, concurrent vehicle
- Details on study design:
- Animals were orally administered from 10 weeks of age including mated up to 3 weeks. The males were necropsied after one week passed after the mating period. Females were allowed to spontaneously deliver after mating and necropsied with their babies on nursing 21th. Both males and females continued to be administered until the day before necropsy, during which the general condition of the parent animal, weight gain and changes in food intake were observed, and at the same time the reproductive ability, including delivery and lactation of the parent animal, and weaning of the infant was observed.
- Maternal examinations:
- Parent animals were observed for mortality, general condition, change in weight, food intake, estrus cycle assessment. Animals were sacrificed to determined presence or absence of abnormalities of major organs thoracic abdomen, including the pituitary glands, stomach, testis, epididymis, coagulated glands, seminal vesicles, and prostate in males and pituitary, stomach, ovary, uterus, cervix and vagina in females
- Ovaries and uterine content:
- Estrus cycle were determined before 2 weeks of start of mating confirmation day, two weeks before the start of administration and two weeks after the start of the administration.
- Fetal examinations:
- Number of births, litter count and weight measurement. Offspings were sacrificed to determined presence or absence of abnormality on the external surface
- Statistics:
- Fisher's direct probability test 1) was carried out on frequency of type of sex cycle, mating rate, conception rate, morphological abnormality frequency of babiesAccording to histopathological examination findings, the Mann-Whitney U test 2)) shows the grade-separated data, and the total value of the positive grade is obtained by Fisher's direct probability one-sided test 3) between the control group and each test substance administration group Significant difference test was carried out. For the other data, we tested the uniformity of variance of each group by Bartlett method 4) , with the value obtained for each individual, or the average value for each litter as one sample . If the variance is uniform, a one-way analysis of variance 4) was performed, and when significance was observed between the groups, multiple comparisons were performed according to the Dunnett method 5) . On the other hand, Kruskal-Wallis 6) rank test is performed when the variance is 0 in any group and when the variance is not uniform, and if significance is observed between the groups.
- Indices:
- Conception rate was determined
- Historical control data:
- No data available
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- Nasal discharge, eyelid ptosis or closed eyes, in group administered with 40 mg / kg or more but not in 160mg/kg group , lacrimation in 160 mg / kg administration group was transiently observed Salivation was observed in each administration group of the test substance.
- Dermal irritation (if dermal study):
- not specified
- Mortality:
- no mortality observed
- Description (incidence):
- In males, one patient in the 160 mg / kg dose group died on the 60th day of administration.
In females, there were no deaths or moribund - Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- No significant difference between the control group and each test group administered group
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- In males no change in food consumption were observed, however in females no change in food consumption uring the period before mating, but significantly lower values than control group, after pregnancy and during the nursing stage
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- not specified
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- no effects observed
- Description (incidence and severity):
- Spontaneous locomotor reduction and salivation were observed transiently after administration and no abnormality was observed in both treated males and femlaes. There was a decrease in locomotor activity, eyelid ptosis or closed eyes, and nasal discharge in group administered with 40 mg / kg or more, lacrimation in 160 mg / kg administration group.
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- not specified
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- There was no change depending on the dose of the test substance in reproductive organsof male and females. Abnormality was not found in the reproductive organs of the 160 mg / kg administration group.
- Neuropathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No abnormality was observed in pituitary gland. In males, in each case in the 40 mg / kg and 160 mg / kg administration groups, the spermatogonia of the spermatogenic cells in the 14 th stage of the spermatogenesis cycle mild degeneration was observed, and cell debris was observed in the lumen of the epididymis in the example of 40 mg / kg administration group. Unilateral seminal vesicle atrophy was observed in each group including the control group. no avnormality were seenon seminal vesicle and Coagulated glands In females, no abnormality was observed in the pituitary gland, stomach, ovary, uterus, cervix and vagina.
- Histopathological findings: neoplastic:
- not specified
- Other effects:
- effects observed, treatment-related
- Description (incidence and severity):
- Hair loss was observed in all the treated animals
- Number of abortions:
- no effects observed
- Pre- and post-implantation loss:
- no effects observed
- Description (incidence and severity):
- Implantation number in treated animals was equivalent to control animals
- Total litter losses by resorption:
- effects observed, treatment-related
- Description (incidence and severity):
- The litter size was significantly low value in 160mg/kg/day group compared to control group.
- Early or late resorptions:
- not specified
- Dead fetuses:
- not specified
- Changes in pregnancy duration:
- no effects observed
- Description (incidence and severity):
- No change in pregnancy duration were seen in treated females.
- Changes in number of pregnant:
- not specified
- Other effects:
- no effects observed
- Description (incidence and severity):
- No abnormality in labor condition was observed, and there was no effect on birth rate
- Dose descriptor:
- NOAEL
- Effect level:
- 160 mg/kg bw/day
- Based on:
- test mat.
- Basis for effect level:
- clinical signs
- mortality
- body weight and weight gain
- food consumption and compound intake
- behaviour (functional findings)
- gross pathology
- histopathology: non-neoplastic
- maternal abnormalities
- pre and post implantation loss
- total litter losses by resorption
- effects on pregnancy duration
- changes in pregnancy duration
- other: labor condition was normal no effect on birth rate
- Fetal body weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Body weight at the postnatal day 21 was slightly lower in the 160 mg / kg administration group
- Reduction in number of live offspring:
- effects observed, treatment-related
- Description (incidence and severity):
- Number of live pups examined reduced in highest dosed group
- Changes in sex ratio:
- no effects observed
- Description (incidence and severity):
- There was no effect of administration on sex ratio
- Changes in litter size and weights:
- effects observed, treatment-related
- Description (incidence and severity):
- The litter size after adjustment of litter size was decreased in 160mg/kg/day group
- Changes in postnatal survival:
- effects observed, treatment-related
- Description (incidence and severity):
- In 160mg/kg /day group the postnatal survival declines comapared to control
- External malformations:
- no effects observed
- Description (incidence and severity):
- No morphological changes including malformations where observed
- Skeletal malformations:
- no effects observed
- Description (incidence and severity):
- No morphological changes including malformations where observed
- Visceral malformations:
- no effects observed
- Description (incidence and severity):
- No morphological changes including malformations where observed
- Other effects:
- no effects observed
- Description (incidence and severity):
- No growth inhibition was observed in the administration group of 40 mg / kg or less
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 40 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- changes in sex ratio
- external malformations
- skeletal malformations
- visceral malformations
- other: No growth inhibition
- Key result
- Developmental effects observed:
- not specified
- Conclusions:
- From the observation and results, the NOAEL for P0 generation and F1 generation was considered to be 160mg/kg/day and 40mg/kg/day respectively.
- Executive summary:
In the present study, developmental toxicity test of test chemical was carried out and the developmental toxicity profile to male and female animals of test chemical was examined. In the study, animals were orally administered from 10 weeks of age including mated up to 3 weeks. The males were necropsied after one week passed after the mating period. Females were allowed to spontaneously deliver after mating and necropsied with their babies on nursing 21th. Both males and females continued to be administered until the day before necropsy, during which the general condition of the parent animal, weight gain and changes in food intake were observed, and at the same time the reproductive ability, including delivery and lactation of the parent animal, and weaning of the infant was observed. The results of the parenteral examination revealed that, no mortality in treated animals at 10, 40 and 160mg/kg/day for 10 weeks,including mating period, the clinical signs examination of animlas shows, nasal discharge, eyelid ptosis or closed eyes, in group administered with 40 mg / kg or more but not in 160mg/kg group , lacrimation in 160 mg / kg administration group was transiently observed. Salivation was observed in each administration group of the test substance.No test chemical related chnages on food consumption and body weight changes were observed. Spontaneous locomotor reduction and salivation were observed transiently after administration and no abnormality was observed in both treated males and femlaes. There was a decrease in locomotor activity, eyelid ptosis or closed eyes, and nasal discharge in group administered with 40 mg / kg or more, lacrimation in 160 mg / kg administration group. There was no change depending on the dose of the test substance in reproductive organsof male and females. The histopathological study relealed no abnormality in pituitary gland. In males, in each case in the 40 mg / kg and 160 mg / kg administration groups, the spermatogonia of the spermatogenic cells in the 14 th stage of the spermatogenesis cycle mild degeneration was observed, and cell debris was observed in the lumen of the epididymis in the example of 40 mg / kg administration group. Unilateral seminal vesicle atrophy was observed in each group including the control group. No abnormality were seen on seminal vesicle and Coagulated glands In females, no abnormality was observed in the pituitary gland, stomach, ovary, uterus, cervix and vagina. The maternal developmental toxicity includes, Implantation number in treated animals was equivalent to control animals. The litter size was significantly low value in 160mg/kg/day group compared to control group. No change in pregnancy duration were seen in treated females. No abnormality in labor condition was observed, and there was no effect on birth rate. The examination of pups revealed, body weight at the postnatal day 21 was slightly lower in the 160 mg / kg administration group. Number of live pups examined reduced in highest dosed group. There was no effect of administration on sex ratio. The litter size after adjustment of litter size was decreased in 160mg/kg/day group. In 160mg/kg /day group the postnatal survival declines comapared to control.No morphological changes including external, skeletal and visceral malformations where seen in treated animals. From the observation and results, the NOAEL for P0 generation and F1 generation was considered to be 160mg/kg/day and 40mg/kg/day respectively.
Reference
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 40 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- The data is K2 level and provides robbust summary
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Additional information
The Developmental Toxicity Data :
Study 2:
In the present study, developmental toxicity test of test chemical was carried out and the developmental toxicity profile to male and female animals of test chemical was examined. In the study, animals were orally administered from 10 weeks of age including mated up to 3 weeks. The males were necropsied after one week passed after the mating period. Females were allowed to spontaneously deliver after mating and necropsied with their babies on nursing 21th. Both males and females continued to be administered until the day before necropsy, during which the general condition of the parent animal, weight gain and changes in food intake were observed, and at the same time the reproductive ability, including delivery and lactation of the parent animal, and weaning of the infant was observed. The results of the parenteral examination revealed that, no mortality in treated animals at 10, 40 and 160mg/kg/day for 10 weeks,including mating period, the clinical signs examination of animlas shows, nasal discharge, eyelid ptosis or closed eyes, in group administered with 40 mg / kg or more but not in 160mg/kg group , lacrimation in 160 mg / kg administration group was transiently observed. Salivation was observed in each administration group of the test substance.No test chemical related chnages on food consumption and body weight changes were observed. Spontaneous locomotor reduction and salivation were observed transiently after administration and no abnormality was observed in both treated males and femlaes. There was a decrease in locomotor activity, eyelid ptosis or closed eyes, and nasal discharge in group administered with 40 mg / kg or more, lacrimation in 160 mg / kg administration group. There was no change depending on the dose of the test substance in reproductive organsof male and females. The histopathological study relealed no abnormality in pituitary gland. In males, in each case in the 40 mg / kg and 160 mg / kg administration groups, the spermatogonia of the spermatogenic cells in the 14 th stage of the spermatogenesis cycle mild degeneration was observed, and cell debris was observed in the lumen of the epididymis in the example of 40 mg / kg administration group. Unilateral seminal vesicle atrophy was observed in each group including the control group. No abnormality were seen on seminal vesicle and Coagulated glands In females, no abnormality was observed in the pituitary gland, stomach, ovary, uterus, cervix and vagina. The maternal developmental toxicity includes, Implantation number in treated animals was equivalent to control animals. The litter size was significantly low value in 160mg/kg/day group compared to control group. No change in pregnancy duration were seen in treated females. No abnormality in labor condition was observed, and there was no effect on birth rate. The examination of pups revealed, body weight at the postnatal day 21 was slightly lower in the 160 mg / kg administration group. Number of live pups examined reduced in highest dosed group. There was no effect of administration on sex ratio. The litter size after adjustment of litter size was decreased in 160mg/kg/day group. In 160mg/kg /day group the postnatal survival declines comapared to control.No morphological changes including external, skeletal and visceral malformations where seen in treated animals. From the observation and results, the NOAEL for P0 generation and F1 generation was considered to be 160mg/kg/day and 40mg/kg/day respectively.
Study 3:
In the present study, developmental toxicity Test of test chemical in Rats was performed to screen the developmental toxicity profile. In the study dose levels of 0, 12.5 ,50 and 200mg/kg used for the 10 weeks of exposure (71 dose administration) including mating period of 3 weeks. The treated animals observed for general condition, body weight measurement and food intake. Red blood cell count and white blood cell count was also measured. Estrus cycle during exposure was estimated. The offsprings were examined for number of births, general condition, number of deceased offspings, litter count, body weight, sex ratio and survival rate were measured.The postmortem of parenteral animals was carried out to examine major thoracic abdominal organs including the pituitary gland, stomach, adrenal glands, testis, epididymis, coagulated glands, seminal vesicles, prostate,ovaries, uterus and vagina. All surviving infants were necropsied by sacrificing all cases by ether inhalation on the 21th birth. At that time, the organ in which abnormality was observed. The dead child was autopsy examined for the presence or absence of abnormality on the external surface. The results of the parenteral observations revealed, transient salivation after test chemical administration in the 200 mg / kg group in both males and female. One case in the control group died due to poor feeding due to irregular occlusion. In addition, each one of 12.5 and 50 mg / kg administration group was moribund slaughtered or died by myeloid leukemia, but neither was caused by administration of the test substance. No death or moribund was observed in other treated animals. In test chemical treated males, suppression of body weight gain was observed at the end of treatment and in females, suppression of body weight gain was observed between the early stage of administration of 200 mg / kg administration group and the middle stage of pregnancy to postpartum nursing, but the effects of administration was not observed in food intake. No change in food consumption were seen at any dose levels at 12.5, 50 and 200mg/kg/day compared to control animals. The increase in the number of red blood cells(RBC) in the administration group of 50 mg / kg or more, no change related to the administration of the test substance was observed. At necropsy, hyperplasia of the forestomach mucosa was observed in the 200 mg / kg dose group.. In the 200 mg / kg administration group, attenuation of the degree of periportal fatty liver in the liver was also observed. For the liver, swelling was also observed at autopsy, but no distinct tissue change associated with swelling was observed. Histopathological examination of tissues revealed, no change due to administration of the test substance. In addition, changes in the pituitary, testis, epididymis, coagulated glands, seminal vesicles and prostate did not occur in any of the administration groups. In females, hyperplasia of squamous epithelium of forestomachial mucosa, but adrenal gland, pituitary gland, ovary , Uterus, uterine cervix and vagina, no change due to administration of the test substance was observed. The examination of neonates revealed, no change on the survivability and no. of pup. However, the body weight of the 200 mg / kg administration group decreased from birth date to 21 days after birth but not in 50mg/kg and lower doses. External malformations such as the tail, short tail, short bending tail or small eye slightly increased in the 200 mg / kg administration group. Abnormalities in the testis and hypoplasia of the spleen and visceral malformation of the diaphragmatic hernia were also observed in 200mg/kg group. At the 200 mg / kg administration group growth inhibition ranging from fetal stage to nursing stage was observed. From the observations and results, the NOAEL for parents and neonates was considered to be 200mg/kg/day and 50mg/kg/day respectively.
Study 4:
The developmental toxicity study of test material was performed according to OECD guideline 414 on rabbits.Young adult nulliparous New-Zealand white strain female and male rabbits (Oryctolagus cuniculus) were used in study. The test material dissolved in 0.5% Carboxymethyl cellulose in dose concentration 0, 3, 10 and 50 mg/kg/day and adminstered by daily gavage through gestation day 6 to 28 to mated females (25/dose group).The preliminary range-finding study (0, 10, 60 and 300 mg/kg/day) was performed, Based on preliminary range-finding study findings, 0, 3, 10 and 50 mg/kg/day were selected for the main study. Animals were observed twice daily for moribundity and mortality. Individual clinical signs were recorded at least once a day during the treatment period and once daily during the pre- and post-treatment periods. Individual body weights were recorded on gestation days 0, 3, 5, 8, 11, 14, 17, 20, 23, 26, 29 and 30. Food consumption per cage of animals were measured over the following periods during gestation: days 0-3, 3- 5, 5-8, 8-11, 11-14, 14-17, 17-20, 20-26, 26-29 and 29-30. On Day 29 of gestation, all the rabbits were sacrificed using intravenous injection of sodium thiopentone. Any gross pathological changes in all the visceral organs of dams were recorded. Organs with macroscopic findings and kidneys were preserved for possible histological evaluation. The ovaries, uteri and uterine contents were removed and examined to determine: the number of corpora lutea, the number of implantations, early and late resorptions, the weight of intact gravid uterus, the number and distribution of live foetuses, the number and distribution of intra-uterine dead foetuses, the individual foetal weight and sex, foetal abnormalities.
There were no maternal death or necropsy findings at any dose levels. There was a significant reduction in the body weight gain during the treatment period in the high dose group (50 mg/kg). The food consumption was comparable to the vehicle control group. The reduction in body weight during the treatment period was considered treatment related. One rabbit aborted in the high dose group, there were 2 non pregnant rabbits in control, 4 in low dose group, 3 in mid dose group and 4 in the high dose group. There was one complete resorption in mid dose group. At the end, at least 20 litters were observed in each of the dose groups. The maternal data parameters comprising of implantations, early and late resorptions, pre and post-implantation loss in all the treatment groups were comparable to the vehicle control group. The mean number of corpora lutea, implantation and live foetus were significantly lower in high dose group (50 mg/kg body weight/day) when compared with the control group. Observed decrease in corpora lutea at 50 mg/kg body weight/day is considered as biological variation because the treatment was initiated after the implantation (gestation day 6). Therefore, the decrease observed in the absolute uterine weight, implantation and live foetus reported at this dose level are also considering as biological variation as these observations are directly correlated with the decrease in the number of the corpora lutea. Hence No Observed Adverse Effect Level (NOAEL) for developmental toxicity was considered to be 50 mg/kg/day,when female rabbits were treated withtest materialorally.
Justification for classification or non-classification
Based on the data available for test chemical, the test chemical does not exhibit reproductive and developmental toxicity by oral route of administration. Hence the test chemical is not likely to classify as a reproductive/ developmentat toxicant as per the criteria mentioned in CLP regulation.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

Route: .live2